The Cancer Precision Medicine Diagnosis and Treatment (K-MASTER) Enterprise
Yoon Ji Choi, Yeul Hong Kim
Korean J Med. 2019;94(3):246-251.   Published online 2019 May 31     DOI: https://doi.org/10.3904/kjm.2019.94.3.246
Citations to this article as recorded by Crossref logo
Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)
Ju Won Kim, Hyo Jin Lee, Ji Yoon Lee, Sook Ryun Park, Yu Jung Kim, In Gyu Hwang, Woo Kyun Bae, Jae Ho Byun, Jung Sun Kim, Eun Joo Kang, Jeeyun Lee, Sang Joon Shin, Won Jin Chang, Eun-Ok Kim, Jason K Sa, Kyong Hwa Park
Journal for ImmunoTherapy of Cancer.2024; 12(3): e008638.     CrossRef